Endpoints News
Neumora will discontinue its lead depression drug Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
15 June, 2026
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
top stories
1. Six leaders working on LGBTQ+ inclusion in biopharma
2. Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff
3. Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
4.
news briefing
Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data
5. Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout
6. German biotech nets $50M to advance two depression drugs, including Spravato challenger
7. FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
8. Eli Lilly invests in startup Abridge for clinical trial recruitment
9. Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
more stories
• 
Karen Weintraub
.

It’s been a tough 18 months for LGBTQ+ communities, but Kyle LaHucik interviewed six people in different roles to check in — and found a surprising amount of optimism. These six bring the total to 68 LGBTQ+ leaders we've profiled over the past five years as part of our annual special report.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Kyle LaHucik

It’s been a tough 18 months for the LGBTQ+ com­mu­ni­ty.

The Amer­i­can Civ­il Lib­er­ties Union tracked530 an­ti-LGBTQ bills across dozens of states this year...

Read the full story
2
by Max Gelman

The Re­al­ly Big Neu­ro­science Com­pa­ny is prov­ing to be a Re­al­ly Big Flop with each pass­ing up­date.

Neumo­ra Ther­a­peu­tics will dis­con­tin­ue its lead de­pres­sion drug...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
3
by Lei Lei Wu

Eli­cio Ther­a­peu­tics’ pan­cre­at­ic can­cer vac­cine failed to im­prove out­comes in a mid-stage study, but the com­pa­ny is seek­ing funds to move ahead to a larg­er...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Sanofi, Phar­ma­Mar, Jazz, Rhythm Phar­ma­ceu­ti­cals, Spyre and Zymeworks

🇨🇳 An­oth­er obe­si­ty read­out from Chi­na: Gan & Lee Phar­ma­ceu­ti­cals, a Chi­na-based in­sulin spe­cial­ist...

Read the full story
5
by Ayisha Sharma

Eli Lil­ly made a push in blood can­cer at this year’s Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion meet­ing in Stock­holm over the week­end.

The drug­mak­er pre­sent­ed da­ta for...

Read the full story
6